Large Cell Neuroendocrine Carcinoma of the Lung with Atypical Evolution and Great Response to Innovative Treatments Abstract #2298

Introduction: Pulmonary neuroendocrine tumors are a group of heterogeneous neoplasms that represent 1% to 2% of all lung cancers.
Aim(s): Case
Materials and methods: A 58yo man went to the Pneumology service for a 1-month evolution productive cough accompanied by hemoptoic sputum and weight loss of approximately 4Kg. in the last 2 months. We realized chest radiography is performed, in which observed a density increase, suggestive of pulmonary nodule, which is confirmed immediately by CT.It was discussed in committee and it was decided to perform right superior lobectomy;The pathology was positive for NEURONDOCRINE CARCINOMA OF LARGE CELLS,2.8cm with mitotic 14 and Ki67>20%,N0.We started adjuvant chemotherapy with Cisplatin/Vinorelbine 4 cycles. In October/09,showed bones recurrence and multiple liver metastases.Treatment with with Cisplatin / Etoposide is offered, progressing after 4 months.It is decided to perform an Octreoscan,being positive.We proposed treatment with Somatostatin analogues.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Roberto Escala
Keywords: LCNEC

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.


Wishing you all the best,

The entire ENETS team